ADAMTS18 not only reverses the resistance of ccRCC to sunitinib and axitinib in combination with curcumin but also independently increases the sensitivity of lung cancer cells to cisplatin (26–28). This evidence concerns the gene ADAMTS18 and nonpapillary renal cell carcinoma.